Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype-Reference-Cited by-同舟云学术

Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype

Published:2017-03-20 Issue:1 Volume:102 Page:123-130
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Roncato R¹,Cecchin E¹,Montico M¹,De Mattia E¹,Giodini L¹,Buonadonna A²,Solfrini V³,Innocenti F⁴,Toffoli G¹

Affiliation:

1. Experimental and Clinical Pharmacology, Centro Di Riferimento Oncologico, National Cancer Institute; Aviano Italy

2. Medical Oncology Unit B, Centro Di Riferimento Oncologico, National Cancer Institute; Aviano Italy

3. Sanitary Direction, Centro Di Riferimento Oncologico, National Cancer Institute; Aviano Italy

4. Eshelman School of Pharmacy; Center for Pharmacogenomics and Individualized Therapy, Lineberger Comprehensive Cancer Center, University of North Carolina; Chapel Hill North Carolina USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference31 articles.

1. List Dosing Guidelines Pharmgkb https://www.pharmgkb.org/view/dosing-guidelines.do?source=CPIC 2016

2. Pharmacogenomics: translating functional genomics into rational therapeutics;Evans;Science,1999

3. Costs and effectiveness of genomic testing in the management of colorectal cancer;Goldstein;Oncology (Williston Park),2015

4. Evidence required to demonstrate clinical utility of pharmacogenetic testing: the debate continues;Gillis;Clin. Pharmacol. Ther.,2014

5. Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians;Liu;Pharmacogenomics J.,2014

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Irinotecan dosing and pharmacogenomics: a comprehensive exploration based on UGT1A1 variants and emerging insights;Journal of Chemotherapy;2024-05-06

2. Implementation of pre‐emptive testing of a pharmacogenomic panel in clinical practice: Where do we stand?;British Journal of Clinical Pharmacology;2023-12-21

3. Cost-utility analysis and cross-country comparison of pharmacogenomics-guided treatment in colorectal cancer patients participating in the U-PGx PREPARE study;Pharmacological Research;2023-11

4. Predicting drug response and toxicity in metastatic colorectal cancer: the role of germline markers;Expert Review of Clinical Pharmacology;2022-06-03

5. Effectiveness and Cost-Utility Analysis of Different Doses of Irinotecan Plus Bevacizumab in Patients With Metastatic Colorectal Cancer: A Long-Term and Prospective Cohort Study;Frontiers in Oncology;2022-03-14